Elise C Hoover
Overview
Explore the profile of Elise C Hoover including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
9
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hoover E, Day E
J Biomed Mater Res A
. 2025 Jan;
113(1):e37867.
PMID: 39760151
Triple-negative breast cancer (TNBC) is infamous for its aggressive phenotype and poorer prognosis when compared to other breast cancer subtypes. One factor contributing to this poor prognosis is that TNBC...
2.
Hoover E, Roy Chowdhury C, Ruggiero O, Day E
ACS Omega
. 2024 Dec;
9(48):47637-47646.
PMID: 39651074
Polymeric nanoparticles (NPs) have shown great promise as highly modifiable platforms that can be applied across many different disease states. They are advantageous because they can encapsulate a range of...
3.
Dang M, Suri S, Li K, Casas C, Stigliano G, Riley R, et al.
Adv Ther (Weinh)
. 2024 Jul;
7(6).
PMID: 39006318
The paucity of targeted therapies for triple-negative breast cancer (TNBC) causes patients with this aggressive disease to suffer a poor clinical prognosis. A promising target for therapeutic intervention is the...
4.
Hoover E, Ruggiero O, Swingler R, Day E
ACS Omega
. 2024 Apr;
9(12):14323-14335.
PMID: 38559981
Doxorubicin (DOX) is a chemotherapy agent commonly used to treat triple-negative breast cancer (TNBC), but it has insufficient efficacy against the disease and considerable toxicity due to its off-target delivery....
5.
Scully M, Wilkins D, Dang M, Hoover E, Aboeleneen S, Day E
Mol Pharm
. 2023 Jul;
20(8):3895-3913.
PMID: 37459272
Overexpression of the antiapoptotic protein B-cell lymphoma 2 (Bcl-2) is correlated with poor survival outcomes in triple-negative breast cancer (TNBC), making Bcl-2 inhibition a promising strategy to treat this aggressive...
6.
Dang M, Hoover E, Scully M, Sterin E, Day E
Curr Opin Biomed Eng
. 2021 Aug;
19.
PMID: 34423177
Antibodies are extremely valuable tools in modern medicine due to their ability to target diseased cells through selective antigen binding and thereby regulate cellular signaling or inhibit cell-cell interactions with...